<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9043">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706454</url>
  </required_header>
  <id_info>
    <org_study_id>RAMBAN-1</org_study_id>
    <nct_id>NCT05706454</nct_id>
  </id_info>
  <brief_title>Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multi- Centre, Adaptive Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KARE Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Open Philanthropy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charak Laboratories India Pvt. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charak Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioLink Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KARE Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet&#xD;
      against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.&#xD;
&#xD;
      Approximately 324 eligible subjects will be randomized in a 1:1 ratio to one of the two&#xD;
      treatment groups.&#xD;
&#xD;
      Group I: Ramatroban 75 mg tablet + Standard of care; Group II: Placebo + Standard of care.&#xD;
&#xD;
      Phase 2&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the safety of Ramatroban 75 mg tablet with the standard of care against Placebo&#xD;
      with the standard of care in COVID-19 hospitalized subjects.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To assess the efficacy of Ramatroban 75 mg tablet with the standard of care against Placebo&#xD;
      with the standard of care in COVID-19 hospitalized subjects.&#xD;
&#xD;
      Phase 3&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the efficacy of Ramatroban 75 mg tablet with the standard of care against Placebo&#xD;
      with the standard of care in COVID-19 hospitalized subjects.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To evaluate the safety of Ramatroban 75 mg tablet with the standard of care against Placebo&#xD;
      with the standard of care in COVID-19 hospitalized subjects.&#xD;
&#xD;
      Long COVID [Follow-up Phase- Objectives- (Phase 2 &amp; 3)]&#xD;
&#xD;
        1. To examine lipid mediators, specifically thromboxane A2, prostaglandin D2,&#xD;
           F2-isoprostane and/or their metabolites in convalescent subjects after treatment.&#xD;
&#xD;
        2. To assess the efficacy of Ramatroban administered during the acute illness in&#xD;
           preventing/mitigating subsequent development of long COVID / PASC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2022</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Parallel Group, Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, Investigator and Outcome Assessor Blinded Method of concealment: Pharmacy-controlled Randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Serious Adverse Events (SAE)</measure>
    <time_frame>Baseline - Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Clinical recovery (TTCR)</measure>
    <time_frame>Baseline - Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of death or need for mechanical ventilation or ECMO</measure>
    <time_frame>Baseline - Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mechanical ventilation or vasopressor therapy, or ECMO</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Baseline-Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Baseline-Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>Baseline-Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who had thrombotic events</measure>
    <time_frame>Within Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Till Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin, platelets, WBC, creatinine, need for renal replacement.</measure>
    <time_frame>Baseline- Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious ventricular arrhythmia</measure>
    <time_frame>censored at hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total red blood cell units transfused</measure>
    <time_frame>Baseline -Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or Clinically Significant Non-Major Bleeding</measure>
    <time_frame>Baseline -Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of inflammation and coagulation markers</measure>
    <time_frame>Baseline- Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Ramatroban 75 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramatroban</intervention_name>
    <description>Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.&#xD;
Subjects will be evaluated over a study period of approximately 365 days.</description>
    <arm_group_label>Ramatroban 75 mg tablet</arm_group_label>
    <other_name>BAYu3405</other_name>
    <other_name>IUPAC Name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered orally twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects of age 18 years and above.&#xD;
&#xD;
          2. Subject (or legally authorized representative) willing to provide informed consent and&#xD;
             agrees to comply with planned study procedures.&#xD;
&#xD;
          3. Subjects hospitalized for SARS-COV-2 infection, having hypoxemia (SpO2: ≤ 93% on room&#xD;
             air) and radiological evidence supporting COVID-19 pneumonia.&#xD;
&#xD;
          4. Subjects meeting 8-point WHO Ordinal Scale 5 or 6&#xD;
&#xD;
          5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial&#xD;
             or public health assay in any specimen, as documented by either of the following:&#xD;
&#xD;
               1. PCR positive in a sample collected &lt; 72 hours prior to randomization; OR&#xD;
&#xD;
               2. PCR positive in sample collected ≥ 72 hours but &lt; 10 days prior to randomization&#xD;
                  AND non-improving or progressive disease suggestive of ongoing SARS-CoV-2&#xD;
                  infection.&#xD;
&#xD;
             i. Note: In case if the subject is not having previous reports, a quantitative&#xD;
             analysis will be performed&#xD;
&#xD;
          6. Women of childbearing potential must agree to either abstinence or use at least one&#xD;
             primary form of contraception not including hormonal contraception from the time of&#xD;
             screening through Day 36.&#xD;
&#xD;
          7. Agrees to not participate in another clinical trial (both pharmacologic and other&#xD;
             types of interventions) for the treatment of COVID-19 through-out the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with immediately life-threatening SARS-CoV-2 infection.&#xD;
&#xD;
             -Life-threatening disease is defined as respiratory failure, septic shock, and/or&#xD;
             multiple organ dysfunction or failure&#xD;
&#xD;
          2. Subjects on invasive mechanical ventilation at screening or randomization.&#xD;
&#xD;
          3. Female subject who is pregnant, breastfeeding, or planning to become pregnant.&#xD;
&#xD;
          4. Subject having other clinically significant gastrointestinal (GI) disease/ GI surgery&#xD;
             that in the opinion of the investigator would interfere with the absorption of&#xD;
             Ramatroban or subject is unable to swallow oral medications.&#xD;
&#xD;
          5. Subject with pre-existing clinically significant spontaneous bleeding abnormality, or&#xD;
             any other condition as per investigator's judgment.&#xD;
&#xD;
          6. Known HIV/Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          7. Severe liver disease (ALT, AST &gt;5 times the upper limit of normal, total bilirubin &gt; 2&#xD;
             times the upper limit of normal).&#xD;
&#xD;
          8. Subject with known severe renal impairment (estimated glomerular filtration rate ≤30&#xD;
             mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,&#xD;
             peritoneal dialysis.&#xD;
&#xD;
          9. Subject participated in any other clinical study using any investigational drug in the&#xD;
             past 30 days before the screening visit.&#xD;
&#xD;
         10. Subject with a history of life-threatening neoplasms within 5 years prior to the&#xD;
             screening visit, other than carcinoma in situ of the cervix or basal cell carcinoma of&#xD;
             the skin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KARE Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Ogletree, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Points &amp; Assists, LLC.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deanna J Nelson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioLink Life Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayashri Krishnan, PhD</last_name>
    <phone>9771407484</phone>
    <email>Jayashri.krishnan@jssresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonika Newar, PhD</last_name>
    <phone>8800799887</phone>
    <email>Sonika.newar@jssresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DEC Health Care</name>
      <address>
        <city>Nellore</city>
        <state>Andhra Pradesh</state>
        <zip>524001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manoj Kumar</last_name>
      <phone>9700487720</phone>
      <email>manojkumarmddec@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shakti Superspecialty Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>382405</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devendra D Gadhadra</last_name>
      <phone>9374643422</phone>
      <email>gadhadradevendra@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lifecare Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400028,</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Gaidhani</last_name>
      <phone>7588606598</phone>
      <email>drsandeepgaidhani@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sangvi Multispecialty Hospital Pvt Ltd</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411027</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Kshirsagar</last_name>
      <phone>9049002749</phone>
      <email>drketan.sangavihospital@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saikrupa Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Sonwane</last_name>
      <phone>9420705185</phone>
      <email>dr.rahulsonawane7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spandan Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prakash Shende</last_name>
      <phone>9822246881</phone>
      <email>deprakashshende1979@gmil.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PDEA'S Ayurved Rugnalaya &amp; Sterling Multispeciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411044</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailesh R Adwani</last_name>
      <phone>7776027744</phone>
      <email>shaileshadwanis@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 23, 2023</study_first_submitted>
  <study_first_submitted_qc>January 28, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 28, 2023</last_update_submitted>
  <last_update_submitted_qc>January 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Ramatroban</keyword>
  <keyword>Post-Acute Sequelae SARS-CoV-2 infection (PASC)</keyword>
  <keyword>Thromboxane</keyword>
  <keyword>Prostaglandin D2</keyword>
  <keyword>F2-Isoprostane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramatroban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

